RVO

Latest News

FDA accepts Regeneron's sBLA for Eylea HD as priority review
FDA accepts Regeneron's sBLA for Eylea HD as priority review

April 17th 2025

The sBLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion, and for broadening the dosing schedule to include every-4-week dosing across approved indications.

Aflibercept: Applications for dosing duration and additional indications pending decision with FDA and EMA
Aflibercept: Applications for dosing duration and additional indications pending decision with FDA and EMA

April 16th 2025

Biocon, Regeneron settle to launch aflibercept biosimilar, Yesafili in the US
Biocon, Regeneron settle to launch aflibercept biosimilar, Yesafili in the US

April 15th 2025

Healthy lifestyles translate to lower risk of retinal disease
Healthy lifestyles translate to lower risk of retinal disease

February 14th 2025

Regeneron announces aflibercept 8mg injection meets primary endpoint in phase 3 QUASAR trial in patients with retinal vein occlusion
Regeneron announces aflibercept 8mg injection meets primary endpoint in phase 3 QUASAR trial in patients with retinal vein occlusion

December 18th 2024

<12
© 2025 MJH Life Sciences

All rights reserved.